Lydia Marcus Post

Lydia Marcus Post

Auto-generated profile, based on publicly available information

Lydia Marcus Post

National Cancer Institute (NCI) 9609 Medical Center Drive

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Cancer Causes & Control
Verified
Journal Article
Open access
PDF file
EVEllen M. Velie
Ellen M. Velie
LMLydia R. Marcus
Lydia R. Marcus
DPDorothy Rybaczyk Pathak
Dorothy Rybaczyk Pathak
AHAnn S. Hamilton
Ann S. Hamilton
RDRalph DiGaetano
Ralph DiGaetano
KSKendra Schwartz
Kendra Schwartz
Purpose: The etiology of young-onset breast cancer (BC) is poorly understood, despite its greater likelihood of being hormone receptor-negative with a worse prognosis and persistent racial and socioeconomic inequities. We conducted a population-based case–control study of BC among young Black and White women and here discuss the theory that informed our study, exposures collected, study methods, and operational results. Methods: Cases were non-Hispanic Black (NHB) and White (NHW) women age 20–49 years with invasive BC in metropolitan Detroit and Los Angeles County SEER registries 2010–2015. Controls were identified through area-based sampling from the U.S. census and frequency matched to cases on study site, race, and age. An eco-social theory of health informed life-course exposures collected from in-person interviews, including socioeconomic, reproductive, and energy balance factors. Measured anthropometry, blood (or saliva), and among cases SEER tumor characteristics and tumor tissue (from a subset of cases) were also collected. Results: Of 5,309 identified potentially eligible cases, 2,720 sampled participants were screened and 1,812 completed interviews (682 NHB, 1140 NHW; response rate (RR): 60%). Of 24,612 sampled control households 18,612 were rostered, 2,716 participants were sampled and screened, and 1,381 completed interviews (665 NHB, 716 NHW; RR: 53%). Ninety-nine% of participants completed the main interview, 82% provided blood or saliva (75% blood only), and SEER tumor characteristics (including ER, PR and HER2 status) were obtained from 96% of cases. Conclusions: Results from the successfully established YWHHS should expand our understanding of young-onset BC etiology overall and by tumor type and identify sources of racial and socioeconomic inequities in BC.

2 October 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
LPLydia Marcus Post
Lydia Marcus Post
DPDorothy Rybaczyk Pathak
Dorothy Rybaczyk Pathak
AHAnn S. Hamilton
Ann S. Hamilton
Kelly A. HirkoKelly A. Hirko
Kelly A. Hirko
RHRichard T. Houang
Richard T. Houang
EVEllen M. Velie
Ellen M. Velie
Background: The role of adult adiposity in young-onset breast cancer (YOBC) subtype risk is not well understood. Methods: In this population-based case (n = 1812)–control (n = 1,381) study of invasive YOBC (ages <50 years), cases were identified from the Los Angeles County and Metropolitan Detroit Surveillance, Epidemiology, and End Results registries, 2010 to 2015. Area-based, frequency-matched controls were sampled from the 2010 Census. General adiposity [body mass index (BMI)] and central adiposity (waist circumference and waist-to-height ratio) across adulthood and covariates were collected from in-person interviews and measurements. ORs and 95% confidence intervals (CI) for adiposity and YOBC tumor subtypes [i.e., luminal A, luminal B, HER2+, and triple negative (TN)] were calculated, overall and by parity, using multivariable weighted logistic regression. Results: Obese young adult BMI was inversely associated with luminal A YOBC (OR = 0.35, 95% CI, 0.16–0.79); other subtype associations were nonsignificant. Similarly, adult overweight and obese BMIs were inversely associated with luminal A (OR = 0.66, 95% CI, 0.48–0.91 and OR = 0.59, 95% CI, 0.46–0.87, respectively), but not other subtypes. Conversely, larger waist circumference was associated with higher odds of luminal B and TN YOBC (OR = 1.48, 95% CI, 1.01–2.15 and OR = 2.48, 95% CI, 1.52–3.88, respectively), but not other subtypes (with similar results for weight-to-height ratio); highest odds were among parous women. Conclusions: Findings show greater general adult adiposity is associated with reduced odds of luminal A YOBC, whereas greater central adiposity is associated with increased odds of luminal B and TN YOBC, particularly among parous women. Impact: Additional studies of central adiposity and YOBC subtype risk, especially incorporating pregnancy history, are warranted.

5 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KDKeith A. Dookeran
Keith A. Dookeran
JGJames M. Groh
James M. Groh
DRDavid G. Ritacco
David G. Ritacco
LMLydia R. Marcus
Lydia R. Marcus
YWYang Wang
Yang Wang
JKJanine Y. Khan
Janine Y. Khan
To assess national expenditure associated with preterm-infant brain MRI and potential impact of reduction per Choosing Wisely campaign 2015 recommendation to “avoid routine screening term-equivalent or discharge brain MRIs in preterm-infants”. Cross-sectional U.S. trend data from the Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP) Kids’ Inpatient Database (KID) database (2006, 2009, 2012, 2016) was used to estimate overall national expenditure associated with brain MRI among infants with gestational age (GA) ≤36 weeks, and also when classified as ‘not indicated’ (NI-MRI) i.e., equivalent to routine use without clinical indications and regarded as low-value service (LVS). Associated cost was determined by querying CMS-database for physician-fee-schedules to find the highest global procedure-cost per cycle, then adjusting for inflation. Sensitivity-analyses were conducted to account for additional clinical charges associated with NI-MRI. 3,768 (0.26%) of 1,472,236 preterm-infants had brain MRI across all cycles (inflation-adjusted total $3,690,088). Overall proportion of brain MRIs increased across 2006–2012 from 0.25%-0.33% but decreased in 2016 to 0.16% (P<0.001). Inflation-adjusted overall expenditure by cycle was: 2006, $1,299,130 (95% CI: $987,505, $1,610,755); 2009, $1,194,208 (95% CI: $873,487, $1,516,154); 2012, $931,836 (95% CI: $666,114, $1,197,156); and 2016, $264,648 (95% CI: $172,061, $357,280). Prevalence for NI-MRI in 2006, 2009, 2012 and 2016 was 86% (n = 809), 88% (n = 940), 89% (n = 1028) and 50% (n = 299), respectively; and 70% were in infants 35–36 weeks GA. NI-MRI prevalence was not different over time by payer-type (Medicaid, private), sex or race/ethnicity (white, black, Hispanic); larger hospital size was significantly associated across 2006–2012 but this declined for all sizes in 2016, with most decline in larger hospitals (P for interaction $1.2 million.

7 May 2026 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
LPLydia Marcus Post
Lydia Marcus Post
LHLauren Hurwitz
Lauren Hurwitz
JFJared A. Fisher
Jared A. Fisher
JKJoel Kaufman
Joel Kaufman
SKStella Koutros
Stella Koutros
RJRena R. Jones
Rena R. Jones
Background: Outdoor air pollution, including fine particulate matter (PM2.5), is an established carcinogen, yet few studies evaluate its associations with prostate cancer risk, and findings are mixed. Methods: We used spatiotemporal prediction models to estimate annual average historical residential PM2.5 (1980-2017) and nitrogen dioxide (NO2) (1990-2017) concentrations for 289 299 men aged 50 years and older in the National Institutes of Health–AARP Diet and Health Study, enrolled from 6 states and 2 metro areas in 1995-1996, followed through 2018. We used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals of associations between 5-year average PM2.5 and NO2 and incident prostate cancer, overall and by tumor aggressiveness (ie, advanced [n = 5791], high-grade [ie, Gleason score ≥8, n = 5793], fatal [n = 3057]). We evaluated interactions with hypothesized effect modifiers. Results: Historical PM2.5 and NO2 concentrations were not associated with prostate cancer risk overall (10-year lagged PM2.5 HR per 5 µg/m3 = 1.00, 95% confidence interval [CI] = 0.98 to 1.02; 10-year lagged NO2 HR per 10 ppb = 1.00, 95% CI = 0.98 to 1.01). Some positive trends were observed for aggressive disease (eg, high-grade: 10-year lagged PM2.5 HR = 1.03, 95% CI = 0.99 to 1.09; advanced: 10-year lagged NO2 HR = 1.04, 95% CI = 0.99 to 1.08). Stratified analyses also showed stronger associations for aggressive disease among Hispanic men (eg, high-grade: NO2 HR = 1.25, 95% CI = 1.05 to 1.48; P = .01 for interaction). Heterogeneity was also evident by urbanicity (high-grade: P = .01 for interaction, PM2.5 and NO2) and state (advanced: P = .05 for interaction, NO2), potentially reflecting air pollution mixture heterogeneity. Conclusions: In this large US cohort, historical residential PM2.5 or NO2 concentrations were not associated with prostate cancer risk overall; however, risk was elevated in some subgroups and for aggressive outcomes. Future evaluation of air pollution mixture components may clarify observed subgroup differences.

2 December 2024
Verified
Other
Open access
LPLydia Marcus Post
Lydia Marcus Post
DPDorothy Rybaczyk Pathak
Dorothy Rybaczyk Pathak
AHAnn S. Hamilton
Ann S. Hamilton
Kelly A. HirkoKelly A. Hirko
Kelly A. Hirko
RHRichard T. Houang
Richard T. Houang
EVEllen M. Velie
Ellen M. Velie
Supplemental Table 2 shows associations between body size throughout adulthood and odds of YOBC subtypes, stratified by race.

2 December 2024
Verified
Other
Open access
LPLydia Marcus Post
Lydia Marcus Post
DPDorothy Rybaczyk Pathak
Dorothy Rybaczyk Pathak
AHAnn S. Hamilton
Ann S. Hamilton
Kelly A. HirkoKelly A. Hirko
Kelly A. Hirko
RHRichard T. Houang
Richard T. Houang
EVEllen M. Velie
Ellen M. Velie
Supplemental Table 4 shows associations between adiposity throughout adulthood and odds of YOBC among premenopausal women